Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows
Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received a placebo, data from a Phase 3 trial shows. Trial results, “Olaparib maintenance therapy following first-line platinum-based chemotherapy in patients with FIGO stage III–IV ovarian cancer (OC)

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *